CTSHNASDAQThe short version
Cognizant Technology Solutions Corporation
Cognizant is one of the world's largest IT-services firms, delivering application, cloud, data and consulting work through a mostly-India workforce; its shares halved in 2026 to about eight times forward earnings even as revenue kept growing.
After an early-2022 peak above $93 and a recovery to $83 at the end of 2025, the shares fell to a $38.73 low in June 2026 and now trade near $44.
$44
Share price
~$21B
Market capitalization
$21.1B
FY2025 revenue
7.7×
Forward P/E
SwipeScroll▾
The statements
A $21bn cash generator growing in the low single digits
FY2020 → FY2025as reported · $
Revenue$21.1B+7%
Operating margin16.1%+1.4pp
Net income$2.2B−0%
EPS$4.56+1%
Free cash flow$2.6B+42%
Open the full statements →As reported, FY2020–FY2025.
- Revenue. Sales reached $21.1 billion in 2025, up 7% — but only about 4% a year compounded since 2018. This is a mature IT-services business growing in the low single digits, neither a compounder nor one falling apart.
- Margins and cash. Operating margin has recovered to 16.1%, and free cash flow has sat in a $1.8–2.6 billion band for years, converting net income at roughly 1.1x once one-off tax items are removed.
- Balance sheet. The company holds more cash than debt — about $1.3 billion of net cash — and returned close to $2.0 billion to shareholders in 2025 through buybacks and a growing dividend.
What the price implies
The market is pricing perpetual decline — across the whole sector
Share-price change, Dec 2025 to mid-July 2026
Every named peer fell 26–48%; the highest-quality franchise fell hardest.
- Priced for decline. Cognizant's ~$19.5B enterprise value on ~$2.4B normalized free cash flow at a 10% cost of equity implies roughly -2% perpetual FCF growth against guided +4% to +6.5% constant-currency revenue, yet every one of its six named peers fell 26% to 48% over the same window (Accenture worst at -48% vs CTSH -47%)
- while Cognizant's own organic constant-currency growth cooled to ~2.9% on flat annual contract value — so the market is pricing an industry-wide, not company-specific, secular decline.
- The condition. At $44 the shares sit ~20% below a ~$55 no-growth floor, so the -2% reads as too pessimistic only if the ~$2.4 billion cash-flow base proves durable; if that base is 15–20% too high, the floor falls toward the high-$30s — near June's $38.38 low.
Capital allocation
The most accretive buyback in its history — but insiders barely own the stock
A fixed $2 billion buys far more stock at $44
| Scenario | Avg price | Shares retired | % of shares out |
|---|---|---|---|
| At Q4 2025 (~$75.40) | $75.40 | 26.5M | 5.5% |
| At mid-2026 (~$44) | $44.00 | 45.5M | 9.5% |
The same $2 billion retires nearly double the shares at today's price.
- Cognizant doubled its 2026 buyback to $2 billion with the stock in the low $40s, ~20% below a ~$55 no-growth free-cash-flow floor, so at ~$44 the program retires about 9.5% of shares a year versus 5.5% at the $75.40 it paid a year earlier — but directors and officers as a group hold only ~0.43% of the stock (~0.13% vested), with a single ~$210k open-market purchase across ~398 Form 4 transactions.
- The catch. That accretion is real only if $44 is genuinely below intrinsic value, so the same $2 billion amplifies the durability bet rather than hedging it; and the ~0.43% insider stake fails this reader's fallen-star-with-strong-insider-ownership screen.
The 2026 derating
Shares halved in seven months while the business kept growing
From $83 at the end of 2025 to a $38.73 low in June 2026; near $44 now.
- What it does. Cognizant bills clients in the US and Europe for technology and business services delivered by a workforce of about 351,600, roughly 73% of it in India — a labor-arbitrage model tied to billable headcount.
- The disconnect. The halving came against results that held: first-quarter 2026 bookings grew 21% to a 1.4x book-to-bill, and management kept full-year revenue guidance at 4–6.5% constant-currency growth.
- The arithmetic. At about $44 the market values the company near one times revenue and roughly eight times forward earnings, with a trailing free-cash-flow yield above 12%.
Revenue mix
Healthcare and banking clients are close to 60% of revenue
2025 revenue by segment
Health Sciences$6.3B30%
Financial Services$6.2B29%
Products & Resources$5.3B25%
Comms, Media & Tech$3.3B16%
FY2025, four reportable segments.
- Concentration. Health Sciences ($6.3bn) and Financial Services ($6.2bn) together are close to 60% of revenue — a defining feature of the demand base and its exposure to two client industries.
- Not founder-led. Founded in 1994, Cognizant is on its third chief executive since founder Francisco D'Souza stepped down; Ravi Kumar S, formerly a president of Infosys, has led since January 2023.
The AI question
Revenue per employee is bending toward AI, not breaking under it
Revenue per employee
Year-end headcount basis; up about 7% over the window.
- The fear. The derating rests on one worry: that generative AI severs the historical link between billable headcount and revenue, collapsing labor arbitrage into a shrinking business.
- The evidence so far. Revenue per head rose from about $56,000 to $60,000 across 2021–2025, fixed-price and outcome-based work is now near half the book, and the most automatable service line grew fastest — the link is bending, not broken.
- Still unproven. The company concedes AI is already replacing some services it used to sell, and the fixed-bid book's margins have not been tested through a full technology transition.
Earnings quality
Reported profit is real cash — converting near 1.1x
Net income, operating and free cash flow
Five-year cash conversion about 1.1x once two one-off tax items are removed.
- Quality. Over 2021–2025 operating cash flow converted net income at about 1.1x; capital spending is under 2% of revenue and stock-based pay under 1%, so profit drops through to cash almost intact.
- Conservative adjustments. The 2024 dip and 2025 spike are two identifiable tax items — a $360m India settlement and a $390m non-cash charge — not deteriorating quality; the 'adjusted' operating margin actually runs below GAAP.
- Watch item. Receivable days have drifted from 77 to 84 as outcome-based work grows — a real cash-timing cost, and the first place a weakening fixed-bid book would show.
Standing among peers
Competitive margins, laggard growth — priced accordingly
Cognizant against its named peers
| Company | 3-yr rev CAGR | Op margin | Trailing P/E |
|---|---|---|---|
| HCLTech | 8.7% | 16.5% | 19.6× |
| Infosys | 6.8% | 20.7% | 15.1× |
| TCS | 5.8% | 24.6% | 16.6× |
| Accenture | 4.2% | 15.6% | 11.2× |
| Cognizant | 2.8% | 16.1% | 9.5× |
| Wipro | 0.8% | 14.5% | 13.1× |
| Capgemini | 0.7% | 11.1% | 9.4× |
The multiple tracks the growth rate almost rank-for-rank.
- Middle of the pack. Cognizant's 16.1% operating margin sits comfortably inside the peer band; what trails is growth — a three-year revenue CAGR near 3% against 6–9% at the faster India-heritage names.
- Earned discount, with a wrinkle. A slower grower with equal margins should trade cheaper — but Cognizant is priced like Capgemini, which grows a third of a percent, despite low-single-digit growth, net cash and steadier cash conversion.
Margin of safety
Four methods land near $60–68 over a $55 no-growth floor
Fair-value estimates vs the ~$44 price
No-growth FCF floor
$55
Sell-side mean target
$64
11–12x forward earnings
$65
2% perpetual-growth DCF
$67
At $44 the buyer gets any future growth for free.
- The floor. Capitalize $2.4 billion of free cash flow at a 10% required return and add net cash, and the business is worth about $55 a share assuming it never grows again — roughly 20% above today's price.
- A re-rating, not a growth bet. The $64 mean target implies only about 11x forward earnings and 2% growth; the multiple need only normalize from eight toward a still-cheap eleven to reach the mid-$60s.
- The condition. Every estimate starts from a durable ~$2.4 billion cash-flow base; if AI compresses labor-arbitrage economics, the floor is not a floor and the implied -2% could prove generous.
Ownership and governance
Clean governance, but management barely owns the stock
0.43%
Owned by all directors and officers
~$210k
Only open-market insider buy, across ~398 Form 4s
12 of 13
Independent directors; one share, one vote
None
Related-party dealings since Jan 2025
- The gap. The register is institutional — index funds are the largest owners — and directors and officers as a group hold about four-tenths of one percent, with a single ~$210,000 open-market purchase into the crash. The conviction signal a fallen-star screen wants is absent.
- Clears the red-flag bar. An independent board, a single share class, no poison pill and no related-party dealings mean the missing insider stake is a missing positive, not a warning sign.
The order book
A fuller order book over a softening demand base
Constant-currency revenue growth
The total line falls mostly as an acquisition anniversaries out; organic cooled from ~4% to ~2.9%.
- Leading indicators up. First-quarter 2026 bookings rose 21% to a 1.4x book-to-bill, one of the strongest quarters in recent history, including a mega-deal above $500 million.
- Coincident line down. Organic growth eased to ~2.9%, annual contract value went flat, and the raised EPS guide is funded by a cost program's savings — with severance charges adjusted out — not by volume.
- The tell. The full-year revenue midpoint leans on a second-half discretionary recovery management concedes it cannot yet see; the next few quarters, not this one, will show which reading holds.
Three paths
The spread runs from sub-$40 to the low-$70s on one question
How the durability question resolves
| Path | What has to hold | Shares worth |
|---|---|---|
| Bear | Organic slides negative as AI deflates pricing | Sub-$40 |
| Base | Organic holds 3–4%, margin gains stick, book converts | ~$60–64 |
| Bull | Organic reaccelerates; AI re-prices revenue upward | Low-to-mid $70s |
At $44 the buyer is priced into the bear path and gets the base and bull outcomes for free.
- Priced below the floor. At $44 the market is paying below even the no-growth value of ~$55 — it is discounting the bear path, so the base and bull outcomes come at no cost if they arrive.
- One unresolved risk. The setup fits a fallen star with a real but conditional margin of safety and clean governance; the open question the record cannot yet settle is whether the near-term pain is cyclical or permanent.
What to watch
Cheap and net-cash, with a real margin of safety — but only if the cash-flow base holds through the AI transition.
- 01Organic constant-currency growth: holding at or above 3% supports the base case; a slide to 1–2% hands it to the bear.
- 02Annual contract value turning positive — demand returning, not just longer-dated, lower-margin cost-takeout work.
- 03Adjusted operating margin holding at 16.0–16.2% without fresh severance add-backs.
- 04A sequential fall in free cash flow that is not explained by working-capital timing.
This distills a guided study built chapter by chapter from the primary filings, calls and market data.
Compiled from the full report · 2026-07-19 · For information, not investment advice.